table_1.PDF

<p>Mastocytosis is a disorder resulting from an abnormal mast cell (MC) accumulation in tissues that is often associated with the D816V mutation in KIT, the tyrosine kinase receptor for stem cell factor. Therapies available to treat aggressive presentations of mastocytosis are limited, thus exploration of novel pharmacological targets that reduce MC burden is desirable. Since increased generation of the lipid mediator sphingosine-1-phosphate (S1P) by sphingosine kinase (SPHK) has been linked to oncogenesis, we studied the involvement of the two SPHK isoforms (SPHK1 and SPHK2) in the regulation of neoplastic human MC growth. While SPHK2 inhibition prevented entry into the cell cycle in normal and neoplastic human MCs with minimal effect on cell survival, SPHK1 inhibition caused cell cycle arrest in G2/M and apoptosis, particularly in D816V-KIT MCs. This was mediated via activation of the DNA damage response (DDR) cascade, including phosphorylation of the checkpoint kinase 2 (CHK2), CHK2-mediated M-phase inducer phosphatase 3 depletion, and p53 activation. Combination treatment of SPHK inhibitors with KIT inhibitors showed greater growth inhibition of D816V-KIT MCs than either inhibitor alone. Furthermore, inhibition of SPHK isoforms reduced the number of malignant bone marrow MCs from patients with mastocytosis and the growth of D816V-KIT MCs in a xenograft mouse model. Our results reveal a role for SPHK isoforms in the regulation of growth and survival in normal and neoplastic MCs and suggest a regulatory function for SPHK1 in the DDR in MCs with KIT mutations. The findings also suggest that targeting the SPHK/S1P axis may provide an alternative to tyrosine kinase inhibitors, alone or in combination, for the treatment of aggressive mastocytosis and other hematological malignancies associated with the D816V-KIT mutation.</p

table_2.PDF

<p>Mastocytosis is a disorder resulting from an abnormal mast cell (MC) accumulation in tissues that is often associated with the D816V mutation in KIT, the tyrosine kinase receptor for stem cell factor. Therapies available to treat aggressive presentations of mastocytosis are limited, thus exploration of novel pharmacological targets that reduce MC burden is desirable. Since increased generation of the lipid mediator sphingosine-1-phosphate (S1P) by sphingosine kinase (SPHK) has been linked to oncogenesis, we studied the involvement of the two SPHK isoforms (SPHK1 and SPHK2) in the regulation of neoplastic human MC growth. While SPHK2 inhibition prevented entry into the cell cycle in normal and neoplastic human MCs with minimal effect on cell survival, SPHK1 inhibition caused cell cycle arrest in G2/M and apoptosis, particularly in D816V-KIT MCs. This was mediated via activation of the DNA damage response (DDR) cascade, including phosphorylation of the checkpoint kinase 2 (CHK2), CHK2-mediated M-phase inducer phosphatase 3 depletion, and p53 activation. Combination treatment of SPHK inhibitors with KIT inhibitors showed greater growth inhibition of D816V-KIT MCs than either inhibitor alone. Furthermore, inhibition of SPHK isoforms reduced the number of malignant bone marrow MCs from patients with mastocytosis and the growth of D816V-KIT MCs in a xenograft mouse model. Our results reveal a role for SPHK isoforms in the regulation of growth and survival in normal and neoplastic MCs and suggest a regulatory function for SPHK1 in the DDR in MCs with KIT mutations. The findings also suggest that targeting the SPHK/S1P axis may provide an alternative to tyrosine kinase inhibitors, alone or in combination, for the treatment of aggressive mastocytosis and other hematological malignancies associated with the D816V-KIT mutation.</p

data_sheet_1.PDF

<p>Mastocytosis is a disorder resulting from an abnormal mast cell (MC) accumulation in tissues that is often associated with the D816V mutation in KIT, the tyrosine kinase receptor for stem cell factor. Therapies available to treat aggressive presentations of mastocytosis are limited, thus exploration of novel pharmacological targets that reduce MC burden is desirable. Since increased generation of the lipid mediator sphingosine-1-phosphate (S1P) by sphingosine kinase (SPHK) has been linked to oncogenesis, we studied the involvement of the two SPHK isoforms (SPHK1 and SPHK2) in the regulation of neoplastic human MC growth. While SPHK2 inhibition prevented entry into the cell cycle in normal and neoplastic human MCs with minimal effect on cell survival, SPHK1 inhibition caused cell cycle arrest in G2/M and apoptosis, particularly in D816V-KIT MCs. This was mediated via activation of the DNA damage response (DDR) cascade, including phosphorylation of the checkpoint kinase 2 (CHK2), CHK2-mediated M-phase inducer phosphatase 3 depletion, and p53 activation. Combination treatment of SPHK inhibitors with KIT inhibitors showed greater growth inhibition of D816V-KIT MCs than either inhibitor alone. Furthermore, inhibition of SPHK isoforms reduced the number of malignant bone marrow MCs from patients with mastocytosis and the growth of D816V-KIT MCs in a xenograft mouse model. Our results reveal a role for SPHK isoforms in the regulation of growth and survival in normal and neoplastic MCs and suggest a regulatory function for SPHK1 in the DDR in MCs with KIT mutations. The findings also suggest that targeting the SPHK/S1P axis may provide an alternative to tyrosine kinase inhibitors, alone or in combination, for the treatment of aggressive mastocytosis and other hematological malignancies associated with the D816V-KIT mutation.</p

Mast Cell Dependent Vascular Changes Associated with an Acute Response to Cold Immersion in Primary Contact Urticaria

<div><p>Background</p><p>While a number of the consequences of mast cell degranulation within tissues have been documented including tissue-specific changes such as bronchospasm and the subsequent cellular infiltrate, there is little known about the immediate effects of mast cell degranulation on the associated vasculature, critical to understanding the evolution of mast cell dependent inflammation.</p> <p>Objective</p><p>To characterize the microcirculatory events that follow mast cell degranulation.</p> <p>Methodology/Principal Findings</p><p>Perturbations in dermal blood flow, temperature and skin color were analyzed using laser-speckle contrast imaging, infrared and polarized-light colorimetry following cold-hand immersion (CHI) challenge in patients with cold-induced urticaria compared to the response in healthy controls. Evidence for mast cell degranulation was established by documentation of serum histamine levels and the localized release of tryptase in post-challenge urticarial biopsies. Laser-speckle contrast imaging quantified the attenuated response to cold challenge in patients on cetirizine. We found that the histamine-associated vascular response accompanying mast cell degranulation is rapid and extensive. At the tissue level, it is characterized by a uniform pattern of increased blood flow, thermal warming, vasodilation, and recruitment of collateral circulation. These vascular responses are modified by the administration of an antihistamine.</p> <p>Conclusions/Significance</p><p>Monitoring the hemodynamic responses within tissues that are associated with mast cell degranulation provides additional insight into the evolution of the acute inflammatory response and offers a unique approach to assess the effectiveness of treatment intervention.</p> </div

Association of histamine and imaging derivatives.

<p>Analysis of mean serum histamine levels for patients (A–C) and controls (D–F) plotted against the composite derivative (i.e. rate of change) of imaging time profiles for all subjects (see methods) for blood flow (A, D), temperature (B, E) and color index (C, F). For example, AU/min is a rate of change of AU with respect to time (dAU/dt). The data supports the association between histamine release as a surrogate marker for mast cell degranulation and vascular changes in those with CUrt, but not healthy subjects.</p

Tryptase-stained skin biopsy.

<p>Skin biopsy in CUrt patient stained for tryptase (red) at baseline at low (10×, upper panels) and high (60×, lower panels) magnification and at 15 minutes following cold stimulation time test (CSTT-see methods).</p

Blood flow, temperature, and skin color images of a representative CUrt subject.

<p>Images at baseline (A, C, E, and G) and at 10 minutes post-CHI (B, D, F, and H) for a CUrt subject (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0056773#pone.0056773.s006" target="_blank">Table S1</a>, Subject 6). Panel A and B, show blood flow images by LSCI; C and D, the temperature images by infrared (IR); E and F, the skin color images by polarized light colorimetry (PLC); and G and H, visible light photography. The blood flow image in A has been scaled up by a factor of 4 for visibility.</p

Maximum response marker: differences between healthy control and CUrt groups for blood flow, temperature, and skin color.

<p>Maximum value above baseline (A, D, and G) and the time it was reached (B, E, and H) were calculated for LSCI (A, B, C), IR (D, E, F), and PLC (G, H, I). Recovery time marker: differences between control and CUrt groups for blood flow, temperature, and skin color. Time of recovery to reach half of maximum for LSCI (G), IR (H), and PLC (I).</p

Comparison of the temperature recovery of a healthy control and CUrt subject.

<p>Region of interest (ROI) of the fingers and hand of a healthy control (A) and a CUrt subject (B), and corresponding time profiles (C and D).</p

Imaging time profiles for healthy controls and CUrt subjects.

<p>Mean blow flow (A), temperature (B), and color index (C) are shown for healthy controls (gray) and patient with Curt (black). For summary data, mean baseline was subtracted from each individual time profile, and then the profiles were smoothed, down-sampled, and averaged based on subject groups. Significant differences between CUrt and control groups are seen for LSCI (A) and IR (B) imagers, but not PLC (C) as calculated by 2-way ANOVA. The dotted horizontal line in panel B represents baseline temperature.</p